These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 27172220)

  • 1. Copy Number Profiling of Brazilian Astrocytomas.
    Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
    G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
    Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma.
    Phillips JJ; Aranda D; Ellison DW; Judkins AR; Croul SE; Brat DJ; Ligon KL; Horbinski C; Venneti S; Zadeh G; Santi M; Zhou S; Appin CL; Sioletic S; Sullivan LM; Martinez-Lage M; Robinson AE; Yong WH; Cloughesy T; Lai A; Phillips HS; Marshall R; Mueller S; Haas-Kogan DA; Molinaro AM; Perry A
    Brain Pathol; 2013 Sep; 23(5):565-73. PubMed ID: 23438035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicentric Glioma Develops via a Mutant IDH1-Independent Pathway: Immunohistochemical Study of Multicentric Glioma.
    Karlowee V; Amatya VJ; Hirano H; Takayasu T; Nosaka R; Kolakshyapati M; Yoshihiro M; Takeshima Y; Sugiyama K; Arita K; Kurisu K; Yamasaki F
    Pathobiology; 2017; 84(2):99-107. PubMed ID: 27553586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults.
    Jha P; Suri V; Singh G; Jha P; Purkait S; Pathak P; Sharma V; Sharma MC; Suri A; Gupta D; Mahapatra AK; Sarkar C
    Diagn Mol Pathol; 2011 Dec; 20(4):225-32. PubMed ID: 22089350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival.
    Korkolopoulou P; Levidou G; El-Habr EA; Adamopoulos C; Fragkou P; Boviatsis E; Themistocleous MS; Petraki K; Vrettakos G; Sakalidou M; Samaras V; Zisakis A; Saetta A; Chatziandreou I; Patsouris E; Piperi C
    Br J Cancer; 2013 May; 108(10):2142-52. PubMed ID: 23619925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFRα activation.
    Azar S; Leventoux N; Ripoll C; Rigau V; Gozé C; Lorcy F; Bauchet L; Duffau H; Guichet PO; Rothhut B; Hugnot JP
    Glia; 2018 Feb; 66(2):239-255. PubMed ID: 29027701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
    Ramkissoon SH; Bi WL; Schumacher SE; Ramkissoon LA; Haidar S; Knoff D; Dubuc A; Brown L; Burns M; Cryan JB; Abedalthagafi M; Kang YJ; Schultz N; Reardon DA; Lee EQ; Rinne ML; Norden AD; Nayak L; Ruland S; Doherty LM; LaFrankie DC; Horvath M; Aizer AA; Russo A; Arvold ND; Claus EB; Al-Mefty O; Johnson MD; Golby AJ; Dunn IF; Chiocca EA; Trippa L; Santagata S; Folkerth RD; Kantoff P; Rollins BJ; Lindeman NI; Wen PY; Ligon AH; Beroukhim R; Alexander BM; Ligon KL
    Neuro Oncol; 2015 Oct; 17(10):1344-55. PubMed ID: 25754088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
    Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL
    Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of the PDGFRA, KIT and KDR genes in glioblastoma: a population-based study.
    Nobusawa S; Stawski R; Kim YH; Nakazato Y; Ohgaki H
    Neuropathology; 2011 Dec; 31(6):583-8. PubMed ID: 21382095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
    Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
    Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
    Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.